• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women

Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women

January 1, 2018
Robert T. Rubin, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Robert T. Rubin, MD Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Weiser M et al, J Clin Psychiatry 2017;78:e758–e765

Since estrogen can affect neurotransmitter functioning, there has been some interest in using estrogen modulators to treat psychiatric conditions, including schizophrenia. Raloxifene is a selective estrogen receptor modulator (SERM) with some preliminary evidence for effectiveness in women with schizophrenia.

In this double-blind, multi-center study, 200 postmenopausal schizophrenic/schizoaffective women were treated for 16 weeks with either raloxifene or placebo augmentation of their antipsychotic drug treatment regimen. The study was conducted at 38 sites in Romania and Moldova, suggesting an average of 5 patients per site. The results were unequivocally negative. Indeed, subjects in the raloxifene treatment group fared significantly worse on the Positive and Negative Syndrome Scale (PANSS) than did the placebo group, an unexpected outcome the authors attribute to chance. There were no significant differences between groups in Clinical Global Impression—Severity or Composite Brief Assessment of Cognition in Schizophrenia scores.

TCPR’s Take
As the authors indicate, their data “does not support the use of raloxifene in severely decompensated schizophrenia patients.” These results are clear, but they may not be definitive. Given the many research sites, the potential for inter-site variability (in diagnosis, conduct of the study, assessments, etc) was quite large. In addition, the postmenopausal schizophrenic women had been ill for an average of over 20 years and had an average of about 20 hospitalizations, suggesting they were refractory to conventional treatments. There is a need for additional studies, with more subjects per site, less-ill women, and perhaps different SERMs.
General Psychiatry
KEYWORDS antipsychotics research-update women's_issues_in_psychiatry
    Robert T. Rubin, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Bipolar Disorder, TCPR, January 2018
    Note From the Editor-in-Chief
    Understanding the Bipolar Spectrum: Tips on Diagnosis
    Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women
    The Bipolar Spectrum: Practical Tips for Diagnosis and Treatment
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.